3 Stocks We Think Could Beat the Market in the Second Half of 2022
Every investor wants alpha -- the extra return above what a benchmark index generates. Many stocks don't deliver alpha at all, but some do.
We asked three Motley Fool contributors to identify stocks they think could beat the market in the second half of the year. Here's why they chose AbbVie (NYSE: ABBV), AstraZeneca (NASDAQ: AZN), and Johnson & Johnson (NYSE: JNJ).
Prosper Junior Bakiny (AbbVie): The year has been good for pharma giant AbbVie, at least so far. The company's shares are performing much better than the S&P 500. AbbVie benefits from the fact that lifesaving medicines are in high demand even during challenging economic periods. Also, the pharma stock was arguably deeply discounted before its recent run of form.
Source Fool.com
